Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

T2EVOLVE

Financiado

Cerrado

Accelerating Development and Improving Access to CAR and TCR engineered T cell t...

Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this ther... ver más

31/12/2025

KLINIKUM DER BAYER...

19M€

Presupuesto del proyecto: 19M€

Líder del proyecto

UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 30 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-11-24

IMI2-2019-18-06: Supporting the development of engin...

I+D

Cerrada hace 5 años

0% 45% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

30 Participantes

KLINIKUM DER BAYERISCHEN JUL...

612.77K€ | Lider

BAYER AKTIENGESELLSCHAFT

500.00K€ | Participante

EUR

78.13K€ | Participante

UNIVERSITY COLLEGE LONDON

471.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CARAT Chimeric Antigen Receptors CARs for Advanced Therapies 6M€ Cerrado

CARiPSCTcells Generation of safe and efficient off the shelf chimeric an... 166K€ Cerrado

CARLY Development and characterization of a novel CAR T-cell thera... 226K€ Cerrado

SynCAR-Ts Synthetic Chimeric Antigen Receptors: Hijacking Nitrenium Io... 3M€ Cerrado

EURE-CART EURopean Endeavour for Chimeric Antigen Receptor Therapies 6M€ Cerrado

RTC2019-007028-1 Desarrollo preclínico y regulatorio de terapias CAR-T modula... 2K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2020-11-24
Fecha Fin: 2025-12-31

Líder del proyecto

UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 19M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct types of cancer but their introduction into clinical practice is hampered by a lack of standardized and validated models to predict safety and efficacy, customized manufacturing and monitoring to scale up production and clinical use to industry standard, and strategies for optimal patient conditioning. The T2EVOLVE consortium unites scientists and physicians, regulators and policy makers, SMEs, and patient stakeholders to tackle these challenges in an orchestrated multi-disciplinary multi-stakeholder approach. A core feature of this approach will be the embedding of patient stakeholders as contributing members of the team across all levels of the R&D process. The overall aim is the development of an innovation ecosystem that will accelerate the process of developing engineered T cell therapy in the EU. The project will deliver novel tools for education and for improving the communication between healthcare providers and patients, optimized laboratory models that can help determine how safe and effective new therapies with engineered T cells are, standardized methods in which these therapies are produced and monitored during treatment. The consortium members are innovators and pioneers in this field that are dedicated to bringing the EU to the forefront of the global engineered T cell therapy movement. This effort will ensure that EU citizens will continue to have access to the most innovative and best-available medical care, provide guidance on how to implement this novel treatment into the EU health care system in a sustainable way, and secure a leading role for Europe in this emerging field in medicine and science, the economy and society.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores